Clinical Trial Update: Study of Alirocumab (REGN727/SAR236553) in Patients With heFH (Heterozygous Familial Hypercholesterolemia) Who Are Not Adequately Controlled With Their LMT (Lipid-Modifying Therapy) [Phase 3]

View source ↗

Summary

Phase 3 study evaluating Alirocumab in patients with heterozygous familial hypercholesterolemia not adequately controlled on lipid-modifying therapy; the trial …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heterozygous Familial Hypercholesterolemia

Drugs mentioned

• alirocumab (alirocumab)

Snippet

Sponsor: Regeneron Pharmaceuticals | Conditions: Heterozygous Familial Hypercholesterolemia | Phase 3 | Status: COMPLETED | Results posted: 2015-10-28